Roche Holding AG revealed plans to launch its sequencing by expansion technology next year, raising the possibility that rival Illumina Inc. could face a real run for its money. Illumina has long ...

Our analyst team just revealed what they believe are the 10 best stocks to ... as well as gene-mapping biotech Illumina on China's "entity list," accusing these two very different companies of ...

As of December 2024, Guardant held $840 million of cash and marketable securities. However, it burned through approximately $390 million in 2022, $345 million in 2023, and $275 million in 2024.

Exact Sciences has a multipronged approach to cancer testing. Current products are Cologuard, its flagship stool-based screening test for colorectal cancer, or CRC, and Oncotype DX, its tissue-based ...

Shares of companies in the lab-tool equipment sector, including Bruker (NASDAQ:BRKR), Illumina (NASDAQ:ILMN), Quanterix (NASDAQ:QTRX), Bio-Techne (NASDAQ:TECH), 10X Genomics, and Qiagen (NYSE:QGEN), ...

In general, tumor cells embody the idea of “the survival of the fittest” gone out of control. Tumor cells outcompete their ...

What risks does Illumina face in the China market? Illumina's challenges in the China market present significant risks to its growth prospects. The company's inclusion on China's Unreliable Entity ...

Financial filings in 2024 revealed that Illumina makes about 7% of its sales from China, and it's unclear whether China's action is a short-term reaction or one with longer consequences.

Genomics company Illumina (NASDAQ:ILMN) will be reporting results tomorrow after the bell. Here’s what investors should know. Illumina met analysts’ revenue expectations last quarter ...

What risks does Illumina face in the China market? Illumina's challenges in the China market present significant risks to its growth prospects. The company's inclusion on China's Unreliable Entity ...